FibroGen (NASDAQ:FGEN – Get Rating) had its price target raised by Cowen to $14.00 in a research report report published on Monday morning, Stock Target Advisor reports.
Several other analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a buy rating to a hold rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a sell rating for the company in a research note on Tuesday, May 24th.
Get
FibroGen alerts:
FibroGen Price Performance
Shares of FGEN opened at $14.59 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.16 and a beta of 0.87. The company has a 50-day moving average of $11.91 and a two-hundred day moving average of $11.98. FibroGen has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to analysts' expectations of $36.15 million. FibroGen had a negative net
margin of 83.64% and a negative return on equity of 100.51%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period last year, the company posted ($1.45) earnings per share. Analysts anticipate that FibroGen will post -3 earnings per share for the current year.
Institutional Trading of FibroGen
A number of institutional investors have recently added to or reduced their stakes in FGEN. Point72 Asset Management L.P. lifted its stake in FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after acquiring an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. bought a new position in shares of FibroGen in the fourth quarter valued at approximately $21,862,000. Federated Hermes Inc. raised its position in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP raised its position in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after purchasing an additional 1,055,536 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after acquiring an additional 748,230 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- Skyworks Solutions Is Worth A Look At These Prices
- 3 Stocks Set to Lead the Nasdaq Bull Market
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
